Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report details a specific share repurchase transaction executed on March 22, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Repurchased: 1,000,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,163.0 pence per share; lowest price paid was 1,151.0 pence per share.
- Treasury Shares Held: 493,224,284 shares (8.70% of total issued share capital; 9.53% of total voting rights).
- Shares in Issue: 5,176,509,485 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 1,000,000 repurchased shares. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cost of the 1,000,000 share repurchase based on the weighted average price between 1,151.0 and 1,163.0 pence.
- Confirm the updated total issued share capital after the cancellation of the repurchased shares.
- Review the remaining authorization for share buybacks under the mandate granted on May 6, 2010.
- Check subsequent filings for the impact of this buyback on earnings per share (EPS) calculations.